Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Construction of PCV (Porcine Circovirus) double subtype ORF2 co-expression vector and vaccine preparation

A co-expression vector, ORF2 technology, applied in the direction of viruses/phages, antiviral agents, virus antigen components, etc., can solve the problem of unsatisfactory prevention and control of circovirus, the protection power cannot reach 100%, and the poor effect of epidemic prevention and control And other issues

Inactive Publication Date: 2015-10-21
ZHEJIANG YEBIO BIOTECH
View PDF9 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the above-mentioned vaccines of different types and subtypes have been launched at home and abroad, the prevention and control effect of circovirus is not satisfactory, and it is still a major epidemic that plagues the breeding industry
As mentioned above, although PCV2a vaccine strains and PCV2b vaccine strains can provide certain cross-protection to each other, due to the differences in antigenicity between PCV2a and PCV2b strains, the protection power cannot reach 100%. One of the main reasons for poor performance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction of PCV (Porcine Circovirus) double subtype ORF2 co-expression vector and vaccine preparation
  • Construction of PCV (Porcine Circovirus) double subtype ORF2 co-expression vector and vaccine preparation
  • Construction of PCV (Porcine Circovirus) double subtype ORF2 co-expression vector and vaccine preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0045] The present invention is based on the PCV2a-2b dual subtype subunit vaccine.

[0046] As used herein, an "immunogenic or immunogenic composition" refers to a composition comprising at least two antigens capable of eliciting cellular and / or antibody-mediated reactions in a host against the composition or vaccine of interest. immune response. Generally, "immune response" includes, but is not limited to, one or more of the following actions: production or activation of antibodies, B cells, helper T cells, suppressor T cells and / or cytotoxic T cells and / or yd T cells, whose specific against an antigen contained in a composition or vaccine of interest. Preferably, the host will exhibit a therapeutic or protective immune response, increasing resistance to emerging infection and / or reducing the clinical severity of the disease. Such protection may be demonstrated by a reduction or absence of symptoms normally exhibited by the infected host, a shorter recovery time, and / or a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to View More

Abstract

The invention relates to construction of a PCV (Porcine Circovirus) double subtype ORF2 co-expression vector and vaccine preparation, in particular to an immunogenic composition, a preparation method and pharmaceutical purposes thereof, and a kit containing the immunogenic composition. The immunogenic composition contains Cap proteins coded by PCV2a ORF2 and Cap proteins coded by PCV2b ORF2. The invention also relates to the PCV double subtype ORF2 co-expression vector, a recombinant shuttle plasmid and recombinant baculoviruses containing the porcine circoviruses namely the PCV2a ORF2 and the PCV2b ORF2. The immunogenic composition can prevent and control the PCV more effectively and more comprehensively, the one-injection double-prevention effect is achieved, the comprehensive protection effect is provided, the number of immune times can be decreased, and the immune cost is reduced.

Description

technical field [0001] The invention relates to the construction of porcine circovirus double-subtype ORF2 co-expression vector and the preparation of subunit vaccine. Background technique [0002] Porcine circovirus (Porcine circovirus, PCV) is one of the smallest animal viruses. The diameter of the virus particle is 17-20nm. It belongs to the genus Circovirus of the Circoviridae family. According to differences in pathogenicity, antigenicity and nucleic acid sequence, PCV can be divided into PCV1 and PCV2. PCV1 is a pollutant of pig kidney cell line and has no pathogenicity to pigs, while PCV2 is pathogenic. PCV2 and its mixed infection with other pathogens have brought great economic losses to the pig industry. Among porcine circovirus diseases (Postwearing multisystemic wasting syndrome, PMWS) and porcine respiratory disease complexes (PRDC) are the most common clinical manifestations. PCV2 infection causes the body to undergo immunosuppression during infection, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/295A61K39/12A61K39/385C12N15/866C12N7/01A61P31/14
Inventor 张鹏超蓝胜芝吴桃芬张婧嵇康
Owner ZHEJIANG YEBIO BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com